ArticleJournal of oncology2021
The Alterations and Potential Roles of MCMs in Breast Cancer.
Article in Journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- The CDK4/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replication.Cell death & disease · 2026Article
- The Role of MCM7 and Its Hosted miR-106b-25 Cluster in Renal Cancer Progression.International journal of molecular sciences · 2025Article
- BALs are prognostic biomarkers and correlate with malignant behaviors in breast cancer.BMC cancer · 2025Article
- MCM4 as Potential Metastatic Biomarker in Lung Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review.Health science reports · 2025Article
- Prognostic and Clinical Significance of the Proliferation Marker MCM7 in Breast Cancer.Pathobiology : journal of immunopathology, molecular and cellular biology · 2025Article
- Expression of gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 in breast cancer patients treated with neoadjuvant chemotherapy: a target molecule or a proliferation marker?Revista da Associacao Medica Brasileira (1992) · 2025Article
- Novel insights into the N 6-methyladenosine modification on circRNA in cancer.Frontiers in oncology · 2025Review
- Review
- Immune modulation and prognostic significance of MCM10 in pan-cancer: a comprehensive analysis.American journal of translational research · 2023Article
- Article
- MCM2 in human cancer: functions, mechanisms, and clinical significance.Molecular medicine (Cambridge, Mass.) · 2022Review
- DEAD-Box RNA Helicases DDX3X and DDX5 as Oncogenes or Oncosuppressors: A Network Perspective.Cancers · 2022Review
- The regulation of PBXs and their emerging role in cancer.Journal of cellular and molecular medicine · 2022Review
- Comprehensive Analysis of the Expression and Prognosis for MCM4 in Uterine Corpus Endometrial Carcinoma.Frontiers in genetics · 2022Article
- Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance.Frontiers in oncology · 2022Review
- Long non-coding RNAs: Biogenesis, functions, and clinical significance in gastric cancer.Molecular therapy oncolytics · 2021Review
- Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer.Frontiers in oncology · 2021Review
- Pharmaceutical characterization and exploration of Arkeshwara rasa in MDA-MB-231 cells.Journal of Ayurveda and integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The minichromosome maintenance (MCM) protein family plays a key role in eukaryotic DNA replication and has been confirmed to be associated with the occurrence and progression of many tumors. However, the expression levels, functions, and prognostic values of MCMs in breast cancer (BC) have not been clearly and systematically explained. In this article, we studied the transcriptional levels of MCMs in BC based on the Oncomine database. Kaplan-Meier plotter was used to analyze prognostic value of MCMs in human BC patients. Furthermore, we constructed a MCM coexpression gene network and performed functional annotation analysis through DAVID to reveal the functions of MCMs and coexpressed genes. The data showed that the expression of MCM2-8 and MCM10 but not MCM1 and MCM9 was upregulated in BC. Kaplan-Meier plotter analysis revealed that high transcriptional levels of MCM2, MCM4-7, and MCM10 were significantly related to low relapse-free survival (RFS) in BC patients. In contrast, high levels of MCM1 and MCM9 predicted high RFS for BC patients. This study suggests that MCM2, MCM4-7, and MCM10 possess great potential to be valuable prognostic biomarkers for BC and that MCM1 and MCM9 may serve as potential treatment targets for BC patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.